Apremilast Accord

Apremilast Accord is a medicine used to treat adults with: - moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in patients who have not responded to or cannot use other systemic (affecting the whole body) treatments for psoriasis, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A). PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘psoralen’ before being exposed to ultraviolet light; - active psoriatic arthritis (inflammation of the joints associated with psoriasis) in patients who cannot take or who have not responded well enough to other treatments called disease-modifying antirheumatic drugs (DMARDs). Apremilast Accord may be used alone or combined with other DMARDs; - ulcers in the mouth caused by Behçet’s disease, an inflammatory disease that may affect many parts of the body. Apremilast Accord is a ‘generic medicine’. This means that Apremilast Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Apremilast Accord is Otezla. Apremilast Accord contains the active substance apremilast.